Lazard Asset Management’s Emergent Biosolutions EBS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-6,344
| Closed | -$30K | – | 2350 |
|
|
2025
Q1 | $30K | Sell |
6,344
-48,959
| -89% | -$232K | ﹤0.01% | 2076 |
|
|
2024
Q4 | $528K | Buy |
55,303
+46,676
| +541% | +$446K | ﹤0.01% | 1351 |
|
|
2024
Q3 | $72K | Sell |
8,627
-92,831
| -91% | -$775K | ﹤0.01% | 1849 |
|
|
2024
Q2 | $691K | Buy |
+101,458
| New | +$691K | ﹤0.01% | 1081 |
|
|
2023
Q4 | – | Sell |
-26,782
| Closed | -$91K | – | 2310 |
|
|
2023
Q3 | $91K | Buy |
+26,782
| New | +$91K | ﹤0.01% | 1667 |
|
|
2023
Q1 | – | Sell |
-4,783
| Closed | -$56K | – | 2363 |
|
|
2022
Q4 | $56K | Buy |
+4,783
| New | +$56K | ﹤0.01% | 1748 |
|
|
2022
Q3 | – | Sell |
-1,782
| Closed | -$55K | – | 2379 |
|
|
2022
Q2 | $55K | Hold |
1,782
| – | – | ﹤0.01% | 1765 |
|
|
2022
Q1 | $73K | Buy |
+1,782
| New | +$73K | ﹤0.01% | 1544 |
|
|
2021
Q4 | – | Sell |
-1,261
| Closed | -$63K | – | 2325 |
|
|
2021
Q3 | $63K | Sell |
1,261
-231
| -15% | -$11.5K | ﹤0.01% | 1573 |
|
|
2021
Q2 | $93K | Sell |
1,492
-369,646
| -100% | -$23M | ﹤0.01% | 1371 |
|
|
2021
Q1 | $34.5M | Buy |
371,138
+21,814
| +6% | +$2.03M | 0.04% | 327 |
|
|
2020
Q4 | $31.3M | Buy |
349,324
+15,206
| +5% | +$1.36M | 0.04% | 343 |
|
|
2020
Q3 | $34.5M | Buy |
334,118
+5,283
| +2% | +$546K | 0.05% | 292 |
|
|
2020
Q2 | $26M | Sell |
328,835
-45,935
| -12% | -$3.63M | 0.04% | 324 |
|
|
2020
Q1 | $21.7M | Sell |
374,770
-164,285
| -30% | -$9.51M | 0.04% | 295 |
|
|
2019
Q4 | $29.1M | Sell |
539,055
-57,140
| -10% | -$3.08M | 0.04% | 281 |
|
|
2019
Q3 | $31.2M | Sell |
596,195
-123,435
| -17% | -$6.45M | 0.05% | 252 |
|
|
2019
Q2 | $34.8M | Buy |
+719,630
| New | +$34.8M | 0.06% | 240 |
|